Depot form of paliperidone is a preparate, which is preferred in patients with treatment incompatibility and applied as an intramuscular injection. Clinicians frequently use it during the recent years. In a study, it was determined that extrapyramidal side effect ratio for the tablet form of paliperidone was the same with placebo (2). In a study conducted with the depot for paliperidone for 52 weeks, EPS ratio was reported as 6%, and it was determined that the most frequent EPS side effect was tremors. In the same study, tardive dyskinesia was
reported only in one patient (3) . Tardive dyskinesia is choreiform, athetoid, or rhythmic, abnormal and involuntary movements that last at least for 4 weeks in the tongue, jaw, body, or the extremities. It was reported in the literature that tardive dyskinesia development rate with the depot form of paliperidone, paliperidone palmitate, was less than 0.2% (4). It is not completely known with which mechanism antipsychotic drugs cause tardive dyskinesia. However, it was reported that hypersensitivity in striatal dopamine receptors, reduction in gamma-amino-butyric acid cycle and free radical induced neurotoxicity and changes in D1 and D2 receptor ratios could be responsible for this movement disorder This letter was accepted for publication in January 13, 2016.
